Brief: Sol Gel Acquires Patidegib

SOL-GEL TECHNOLOGIES

27/01/2023 12:10

Jan 27 (Reuters) - Sol Gel Technologies Ltd  SLGL.O :
    * SOL GEL TECHNOLOGIES LTD - PHASE 3 STUDY EXPECTED TO
INITIATE IN
SECOND HALF OF 2023, WITH RESULTS EXPECTED BY END OF 2025
    * SOL-GEL ACQUIRES PATIDEGIB, A PHASE 3,
FDA-BREAKTHROUGH-DESIGNATED ORPHAN PRODUCT CANDIDATE TO PURSUE
POTENTIAL MARKET OF OVER $300 MILLION
    * SOL-GEL ACQUIRES PATIDEGIB, A PHASE 3,
FDA-BREAKTHROUGH-DESIGNATED ORPHAN PRODUCT CANDIDATE TO PURSUE
POTENTIAL MARKET OF OVER $300 MILLION
    * SOL GEL TECHNOLOGIES LTD - PHASE 3 STUDY EXPECTED TO
INITIATE IN
SECOND HALF OF 2023, WITH RESULTS EXPECTED BY END OF 2025
    * SOL GEL TECHNOLOGIES LTD - ESTIMATE THAT SGT-610, IF
APPROVED BY
FDA, HAS POTENTIAL TO GENERATE, AT PEAK, ANNUAL NET SALES IN
EXCESS OF $300 MILLION
    * SOL GEL TECHNOLOGIES - WILL PAY PELLEPHARM UPFRONT PAYMENT
OF
$4.7 MILLION AND TOTAL DEVELOPMENT AND NDA ACCEPTANCE MILESTONES
OF UP TO $6.0 MILLION
    * SOL GEL TECHNOLOGIES - WILL PAY PELLEPHARM UP TO $64.0
MILLION
IN COMMERCIAL MILESTONES AS WELL AS SINGLE DIGIT ROYALTIES

Source text for Eikon:  ID:nGNX1t4BSb 
Further company coverage:  SLGL.O 
 ((Reuters.Briefs@thomsonreuters.com;))